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Autophagy is an essential cellular process affecting virus infections and other diseases and
Beclin1 (BECN1) is one of its key regulators. Here, we identiﬁed S-phase kinase-associated
protein 2 (SKP2) as E3 ligase that executes lysine-48-linked poly-ubiquitination of BECN1,
thus promoting its proteasomal degradation. SKP2 activity is regulated by phosphorylation in
a hetero-complex involving FKBP51, PHLPP, AKT1, and BECN1. Genetic or pharmacological
inhibition of SKP2 decreases BECN1 ubiquitination, decreases BECN1 degradation and
enhances autophagic ﬂux. Middle East respiratory syndrome coronavirus (MERS-CoV)
multiplication results in reduced BECN1 levels and blocks the fusion of autophagosomes and
lysosomes. Inhibitors of SKP2 not only enhance autophagy but also reduce the replication of
MERS-CoV up to 28,000-fold. The SKP2-BECN1 link constitutes a promising target for host-
directed antiviral drugs and possibly other autophagy-sensitive conditions.
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Macroautophagy (subsequently referred to as autophagy) isa conserved cytosolic degradation process in eukaryotesthat maintains macromolecule, energy and organelle
homeostasis1. It requires a ﬁne-tuned sequence of molecular
actions largely executed by autophagy-related genes (ATGs). In the
initial steps, a phagophore consisting of a double-membrane sheet
is nucleated, ampliﬁed and ﬁnally closed to form a vesicular
structure called an autophagosome that engulfs cellular material for
degradation1. Degradation is accomplished after the fusion of
autophagosomes (AP) with lysosomes to form autolysosomes (AL).
A more recently emerged regulator of autophagy is the HSP90
cochaperone FK506 binding protein (FKBP)512. In general,
FKBP51 is a stress-regulated protein involved in numerous
pathways, likely through scaffolding regulatory protein interac-
tions3. FKBP51-induced autophagy is accompanied by elevated
levels of Beclin1 (BECN1) through a yet unknown mechanism.
This multifunctional protein is crucial in autophagy and mem-
brane trafﬁcking processes4. In mammals, BECN1 is an essential
component of two phosphatidylinositol 3-kinase (PI3K) com-
plexes through its interaction with either Barkor (BECN1-asso-
ciated autophagy-related key regulator)/ATG14 or UVRAG (UV
radiation resistance-associated gene)5. The ATG14-complex is
important for the initial nucleation steps of autophagy, whereas
the UVRAG containing complex functions in endocytic traf-
ﬁcking and autophagosomal maturation. ATG14 is also found on
mature autophagosomes where it enhances tethering and fusion
of autophagosomes with lysosomes6.
The regulation of BECN1 through post-translational mod-
iﬁcation is well documented, and in particular involves phos-
phorylation and ubiquitination4. The oncogenic kinase AKT1
phosphorylates BECN1 at positions S234, S295, which leads to
sequestration of this peripheral membrane binding protein7 to
the cytoskeleton with the result of inhibition of autophagy8.
Several other autophagy-regulating kinases (both stimulatory and
inhibitory) also target BECN14. Furthermore, distinct E3 ligases
of different types modify BECN1 with K11-, K48- or K63-linked
poly-ubiquitins9, complemented by ubiquitin-speciﬁc peptidases
(USPs)10,11. Depending on the site and type of linkage of BECN1
ubiquitination, autophagy is inhibited or enhanced; the under-
lying mechanisms involve degradation of BECN1 and modulation
of its protein interactions9,12.
Studies investigating the interplay between autophagy and
viruses revealed that some viruses use parts of the autophagy
machinery for their own replication but also have evolved stra-
tegies to escape autophagic degradation. Congruently, autophagy-
inducing agents can have antiviral effects13. In case of cor-
onaviruses (CoV), the formation of replication complexes at
double membrane vesicles (DMV) and, most likely, of infectious
particles depend on ER-derived membranes, as does autop-
hagy14–16. Thus, current knowledge suggests that CoV interact
differentially with components of the autophagic pathway with
the potential for both the utilization of autophagy components for
virus replication and for the attenuation of autophagy17. Sub-
stances inhibiting the generation of DMVs have been shown to be
broadly reactive against CoV replication in vitro18. Importantly,
this included CoV of different genera including the emerging
Middle East respiratory syndrome (MERS)-CoV, a paradigmatic
emerging virus that entails considerable pandemic risks due to its
prevalence in dromedary populations in Africa and the Arabian
Pensinsula and its transmission via the respiratory tract causing a
severe form of pneumonia in humans18–21. Since its discovery in
2012, the WHO has reported 2468 human MERS-CoV infections
in 27 countries, of which at least 851 were fatal (http://www.who.
int/emergencies/mers-cov/en/).
Currently, there is no clinically-approved treatment for MERS-
CoV infection. While holding promise as a broad-range host-
directed antiviral target, in general13, the role of autophagy in the
MERS-CoV life cycle, if any, is unknown. Nevertheless, a kinome
analysis of MERS-CoV-infected cells detected phosphorylation
changes of several regulatory kinases including AKT1 and mTOR
that have been linked to autophagy in other studies22,23. Although
pharmacological interventions of broadly active AKT1- and
mTOR-pathway inhibitors showed promise for antiviral therapy
against several viruses including MERS-CoV22, the identiﬁcation
of downstream molecules may facilitate a more targeted ther-
apeutic approach with putative reduced side effects in patients.
A role of autophagy is suggested for another CoV, the mouse
hepatitis virus (MHV), by the observation that multiplication of,
and immune evasion by the virus is highly dependent on the
formation of convoluted membranes and DMVs that are remi-
niscent of autophagosomes24. However, the link of MHV repli-
cation to these DMVs did not appear to involve autophagy as the
deletion of the pivotal autophagy genes ATG7 or ATG5 did not
affect MHV replication25,26. Of note, also the induction of
autophagy by starvation did not signiﬁcantly change MHV
replication26. On the other hand, results of an earlier study
employing ATG5 knockout cells suggested that autophagy is
required for the formation of DMV-bound MHV replication
complexes thereby signiﬁcantly enhancing the efﬁciency of viral
replication16. Furthermore, pharmacological or genetic manip-
ulation of autophagy showed that replication of another CoV, the
Transmissible Gastroenteritis virus (TGEV), is negatively regu-
lated by autophagy27. In contrast, another study reported
enhancement of TGEV replication by autophagy28. Thus, no
general role of autophagy in CoV replication could be
established yet.
Here, we aim to elucidate the mechanisms controlling BECN1
protein levels. We ﬁnd that S-phase kinase-associated protein 2
(SKP2) executes lysine-48-linked poly-ubiquitination of BECN1;
its activity is regulated through phosphorylation under the con-
trol of FKBP51 involving AKT1 and PHLPP. Small molecule
inhibitors of SKP2 enhance autophagy and reduce replication of
MERS-CoV, pointing to the prospect of their therapeutic
usefulness.
Results
FKBP51 increases BECN1 stability. In search for a mechanism
of the previously reported increase of the pivotal autophagy reg-
ulator BECN1 driven by FKBP512 we considered effects on
mRNA and protein level. In direct comparison to the highly
homologous FKBP52, a known counter-player of FKBP5129, only
FKBP51 increased BECN1 levels upon ectopic expression3
(Fig. 1a). Regulation of BECN1 protein stability through the
ubiquitin-proteasome system was indicated by using the protea-
some inhibitor MG132, which increased the levels of BECN1 and
the extent of its ubiquitination (Fig. 1b, Supplementary Fig. 1a).
The use of ammonium chloride to inhibit lysosome-mediated
proteolysis conﬁrmed proteasomal degradation of BECN1 (Sup-
plementary Fig. 1b). Ectopic expression of FKBP51 was similarly
efﬁcient in stabilising BECN1 as proteasome inhibition by MG132
(Fig. 1c, d). A protein degradation assay based on a pulse-chase
using Halo-tagged BECN130 conﬁrmed that FKBP51 stabilises
BECN1 (Fig. 1e, f). These results also revealed a high turn-over
rate of BECN1 (t1/2 < 1 h).
FKBP51 associates with SKP2 regulating BECN1 stability.
FKBP51 recently emerged as a scaffolder protein organising
various regulatory protein complexes2,31–33. We thus considered
an FKBP51-controlled association of BECN1 with E3 ubiquitin
ligases or USPs. Based on the results of an FKBP51 mammalian-
2-hybrid interaction screen34, we ﬁrst veriﬁed the association of
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FKBP51 with the USPs 18 and 36, and with the E3 ligase SKP2 by
immunoprecipitation in HEK293 cells (Fig. 2a). TRAF6 that is
known as an E3 ligase of BECN135 and interactor of FKBP5136
served as a control. Of these FKBP51 interactors, SKP2, USP18
and USP36 have the potential to inﬂuence K48-linked poly-ubi-
quitination of BECN1. Co-immunoprecipitations of BECN1 in
HEK293 cells revealed association with SKP2 only (Fig. 2b),
which has not been described as an E3 ligase of BECN1 before.
However, inhibition of SKP2 has been previously linked to
induction of autophagy37,38.
Since we aimed at understanding the mechanism of FKBP51-
directed increase in BECN1, we focussed in the following on
proteins we found associated with both FKBP51 and BECN1. To
assess the effect of SKP2 on BECN1 stability, we monitored the
protein levels of BECN1 after the addition of the translation
inhibitor cycloheximide (CHX) in the presence of over-expressed
SKP2 or TRAF6 (again used as control), respectively. SKP2
affected BECN1 stability, leading to faster proteasomal degrada-
tion, while the K63-E3 ligase TRAF6 had no effect (Fig. 2c, d).
Similar results were obtained in a pulse-chase experiment
showing that SKP2 reduced BECN1 by about 20% compared to
the vector control already at 30 min (Fig. 2e, f).
Further corroborating the function of SKP2 on BECN1, siRNA
directed against Skp2 produced increased levels of BECN1 and
the SKP2 target P27 along with enhanced lipidation of LC3B
(typically detected as the ratio LC3B-II/I) (Fig. 2g, Supplementary
Fig. 1c). Ectopic expression of SKP2 exerted the opposite effect
(Fig. 2h, Supplementary Fig. 1d). Decreasing SKP2 by siRNA
prevented BECN1 ubiquitination (Fig. 2i). In addition, stability
assays using either CHX or the Halo-tagged BECN1 further
established that reducing SKP2 levels with siRNA increases
BECN1 stability leading to almost 3-fold higher levels at 90 min
(Fig. 2j–m).
Phosphorylation-controlled ubiquitination of BECN1 by
SKP2. Next, we examined whether SKP2 ubiquitinates BECN1.
Ubiquitination frequently forms chains linking several ubiquitin
units to distinct lysine (K) residues. The type of lysine linkage
determines protein fate and function39. Using a set of ubiquitin
mutants, we found that SKP2 leads to K48-linked poly-ubiquiti-
nation (Fig. 3a), which marks proteins for proteasomal degrada-
tion39. Using a freely available mass-spectrometry database that
proposes ubiquitination sites in mammalian proteins40, we muta-
ted various lysines in BECN1 and identiﬁed K402 in BECN1′s
ECD (evolutionary conserved domain) as the attachment site of
SKP2-directed ubiquitination (Fig. 3b, Supplementary Fig. 1e). The
potential recruitment of SKP2 by FKBP51 raises the question how
this may lead to reduced rather than increased ubiquitination of
BECN1. Since FKBP51 inactivates the kinase AKT1 through
complex formation with the phosphatase PHLPP2,31, and AKT1
regulates SKP2 through phosphorylation at S7241, we used ectopic
expression of FKBP51-Flag and co-immunoprecipitation to probe
for protein interactions and the phosphorylation status of SKP2.
The association between FKBP51 and BECN1, AKT1, PHLPP, and
SKP2 was accompanied by a decreased phosphorylation of AKT1
at position S473 and of SKP2 at position S72 (Fig. 3c–e).
These results suggest a mechanism where FKBP51 enacts a
cascade of activity changes in AKT1 and SKP2 by the recruitment
of PHLPP (Fig. 4a). We followed several approaches to
substantiate the functionality of this cascade, ﬁrst by employing
SKP2 mutants that either mimic phosphorylation (S72D/S75D)
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Fig. 1 FKBP51 increases BECN1 stability. a FKBP51 increases BECN1 protein levels. HEK293 cells were transfected with either Flag-tagged FKBP51 or
FKBP52 expressing plasmid or control vector. BECN1 mRNA and protein were determined after 72 h. b BECN1 is subject to proteasomal degradation.
HEK293 cells were transfected with Ubiquitin-HA expressing plasmid and treated with the proteasome inhibitor MG132 (10 µM, 2 h) as indicated. BECN1
was immunoprecipitated from whole cell extracts and probed for ubiquitination by western blotting (quantiﬁcation Supplementary Fig. 1a). c–f FKBP51
delays degradation of BECN1. HEK293 cells were transfected with vector control (Co) or FKBP51 expressing plasmid for 72 h and treated with the
translation inhibitor cycloheximide (CHX, 30 µg mL−1) as indicated in c, d. In e, f, HEK293 cells were transfected with Halo-tagged BECN1 expressing
plasmid together with FKBP51-Flag expressing plasmid or vector, cultivated with halogenated dye (100 nM, R110Direct, pulse) overnight, switched to
medium without dye (chase) and treated with MG132 or vehicle for the indicated times. In all panels, error bars denote the standard error of the mean,
derived from n= 3 biologically independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA in a, two-way ANOVA in d, f details in
Supplementary Table 1). Source data and blot collections are provided as a Source Data ﬁle.
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or cannot be phosphorylated (S72A)41. The phosphomimetic
mutant still decreased BECN1 stability, but the S72A mutant
showed no effect (Fig. 4b, c), consistent with the proposed
cascade (Fig. 4a). We further made use of a well-established
PHLPP inhibitor42 that led to enhanced phosphorylation of
AKT1 and SKP2 (Fig. 4d, Supplementary Fig. 1f). A pulse-chase
assay showed that the stability of BECN1 decreased by using
the PHLPP inhibitor (Fig. 4e, f). This inhibitor had no effect on
the stability of the ubiquitination-protected K402R mutant of
BECN1, further corroborating the proposed cascade (Fig. 4g, h).
In addition, pharmacological inhibition of AKT1 enhanced
BECN1 stability in both assays, leaving about twice the amount
of BECN1 at 90 min compared to control (Fig. 4i–l). In order to
verify that reduced SKP2 activity drives autophagy in our cellular
set-up, we used siRNA and determined the degradation of long-
lived proteins43. Targeting SKP2 increased proteolysis, but not in
the presence of the autophagy inhibitor 3-methyladenine (3-MA,
Fig. 4m). Furthermore, we observed decreased levels of P62
(Supplementary Fig. 1g), which typically goes along with
enhanced autophagy43. All these data are consistent with an
inhibitory effect of SKP2 on autophagy regulated by a
phosphorylation cascade involving FKBP51, PHLPP and AKT1.
Small molecule inhibitors of SKP2 increase BECN1 stability.
Next, we compared known small molecule inhibitors of SKP244–46
and found increased stability of BECN1 after a 90min exposure to
SMER3 (leaving about twice as much BECN1 at 60 and at 90min
compared to vehicle control, p < 0.001), and SMIP004 in particular
(virtually no degradation vs. 78% decrease at 90min, p < 0.001),
b
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while compound C1 had no effect (Fig. 5a, Supplementary
Fig. 2a). The pulse-chase assay conﬁrmed SMIP004 as the most
efﬁcient compound in stabilising BECN1 leaving threefold more
BECN1 protein after 90min (Fig. 5b). Furthermore, SMIP004
reduced ubiquitination of BECN1 most efﬁciently (Fig. 5c, last
lane). The long-lived protein assay revealed that SMER3 and
SMIP004 enhanced protein half-life, while C1 showed no effect
(Fig. 5d). Starvation by cultivating the cells in HBSS, which we
conﬁrmed to induce autophagy (Supplementary Fig. 2b-d), did
not elicit a greater effect than SMIP004 in the long-lived protein
assay (Fig. 5d). Furthermore, SMIP004 most profoundly affected
not only BECN1, but also LC3B-II/I and P62 (example blot in
Fig. 5e, quantiﬁcations in Supplementary Fig. 2e-g) that are
established markers of autophagy. To analyse autophagy more
thoroughly, it is mandatory to include assays that address
autophagic protein turn-over, commonly referred to as autophagic
ﬂux43. Thus, we subjected SMIP004 to a ﬂux assay with the spe-
ciﬁc inhibitor of vacuolar H+ -ATPases baﬁlomycin A1 (BafA1),
which interferes with lysosome acidiﬁcation and thus degradation
of autophagosome cargo43. We revealed a stimulatory effect of
SMIP004 on the autophagic ﬂux (Fig. 5f, Supplementary Fig. 2b,
c). In addition, it has been shown that ATG14 oligomerizes to
dimers and tetramers, which is essential for autophagy by pro-
moting STX17 binding and autophagosome-lysosome fusion6.
Using capillary-based electrophoresis allowing for better resolu-
tion at high molecular weight we observed ATG14 oligomerization
to 7–8mers, which was enhanced by SMIP004 (Supplementary
Fig. 2h, i). Thus, SMIP004 was used as SKP2-inhibitor (SKP2i) in
all subsequent experiments.
MERS-CoV decreases autophagy. Results up to this point sug-
gested that activity of BECN1 and thereby autophagy is limited by
SKP2, which in turn is activated by AKT1 (41 and Figs. 3, 4).
Since MERS-CoV has been shown to enhance phosphorylation of
AKT122, it might reduce autophagy. Infection of VeroB4 cells
with MERS-CoV facilitated increased phosphorylation of SKP2 at
S72 (Fig. 6a, Supplementary Fig. 3a), with a concomitant decrease
of cellular levels of BECN1 (Fig. 6a, Supplementary Fig. 3b) and
enhanced K48-polyubiquitinylation of BECN1 (Fig. 6b). Infection
with MERS-CoV further led to an increase of the total number of
phagocytic vesicles (sum of AL+AP) per cell (Fig. 6c, d).
However, the number of successfully formed AL was reduced
signiﬁcantly indicating that AP can form but not fuse with
lysosomes when cells are infected. A fusion block was also evi-
denced by the signiﬁcantly reduced ATG14 oligomerization,
essential for AP-lysosome fusion6, in infected cells (Fig. 6e, f) and
by the increase of the autophagy target P62 (Supplementary
Fig. 3c). The block of vesicle fusion was further tested by the use
of BafA1: as expected, LC3B-II/I levels were not further enhanced
upon treatment with BafA1 (Fig. 6g). The fusion between AP and
lysosome membranes is facilitated by the interaction between
tSNARE proteins STX17 (AP-bound) and VAMP8 (lysosome-
bound). This interaction is mediated by SNAP2947 (Supplemen-
tary Fig. 3d). Co-immunoprecipitation revealed that MERS-CoV
infection leads to a reduced interaction of STX17 with SNAP29
and VAMP8 (Fig. 6h). This further supports the conclusion that
MERS-CoV infection causes a block of AP-lysosome fusion.
Since the results so far raised the possibility that MERS-CoV
may beneﬁt from reducing autophagy, we generated VeroB4 cells
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with a knockout of the pivotal autophagy gene ATG5. Compared
to WT cells, infection of VeroB4 Atg5-KO cells led to the
formation of 52-fold more infectious viral particles (Fig. 7a) while
genomic viral RNA copies only increased by 6-fold (Fig. 7b). The
efﬁcient formation of DMVs is required for CoV replication and
might exploit autophagy or its components25. CoV-induced
DMV formation is known to depend on viral nonstructural
proteins (NSP) 4 and 618,48,49. Ectopic expression of MERS-CoV
NSP4 and 6 indeed led to an accumulation of LC3B-II/I and of
P62 in the case of NSP6, while NSP4 only had a very minor effect
on LC3B-II/I (Fig. 7c). This suggested a block of the autophagic
ﬂux by NSP6, which was conﬁrmed by using BafA1 (Fig. 7d),
altogether suggesting the MERS-CoV-induced inhibition of
autophagic ﬂux to be mediated mainly by NSP6.
CoV have group-speciﬁc accessory proteins that can modulate
viral replication and immune evasion50,51. To assess potential
autophagy-related functions, we overexpressed all MERS-CoV
accessory genes 3, 4a, 4b, and 5. Protein 4b and 5, but not 3 and 4a,
caused accumulation of P62 and enhanced the level of LC3B-II/I
similar to Baf1A, which produced an additional effect in the
presence of p3 or p4a, but not p4b or p5 (Fig. 7e, f). Because p4b
and p5 are accessory proteins that can be deleted without lethal
effects on virus replication, we constructed recombinant MERS-
CoVs lacking the respective orfs (Supplementary Fig. 4a, b) to
evaluate their effect on autophagy in the context of full virus
replication. In comparison to the recombinant MERS-CoV the
p4b- and p5-deletion variants showed a decreased accumulation of
P62 and LC3B-II/I, suggesting that both proteins contribute to the
inhibition of the autophagic ﬂux (Supplementary Fig. 4c, d). The
p4b- and p5-deleted viruses as well as the WT control virus grew to
higher levels in Atg5 knockout Vero cells compared to WT cells
(Supplementary Fig. 4e, f). However, the p4b and p5-deleted
a
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viruses showed overall an up to 10-fold decreased replication in
both WT and Atg5 knockout cells compared to WT virus
suggesting a p4b- and p5-dependent attenuation of virus
replication that is independent of ATG5-directed autophagy.
SKP2 inhibition reduces MERS-CoV replication. The inﬂuence
of MERS-CoV infection on SKP2 phosphorylation, BECN1
degradation and its inhibition of the autophagic ﬂux encouraged
us to test if SKP2 inhibitors (such as SKP2i) may limit MERS-
CoV ampliﬁcation in infected cells. Indeed, SKP2i caused
signiﬁcant reduction of viral replication (by about 250-fold,
Fig. 8a, Supplementary Fig. 5a). To explore the relevance of SKP2
inhibition on viral infection in more general terms, we also tested
SKP2i in Sindbis virus (SINV) replication. It is known that SINV
induces autophagy but that its replication levels are unaffected by
it52. We observed that treatment with SKP2i caused a moderate
decrease of SINV replication (Supplementary Fig. 5b, c). SKP2i
may thus be exploitable as a broader therapeutic antiviral
principle.
As high concentrations of SKP2i inhibit the cell cycle44, it was
mandatory to control for potential cell cycle effects in VeroB4
cells that may partly account for the observed inhibition of
MERS-CoV replication. FACS-based analysis of VeroB4 cells
revealed effects on cell proliferation occur only at concentrations
of SKP2i beyond 10 µM (Supplementary Fig. 6). Accordingly,
while SKP2i enhanced the levels of BECN1 already at 1 µM, no
signiﬁcant increase in the cell cycle promoter P27 was observable
up to 100 µM (Supplementary Fig. 7a).
Our data strongly suggest that of the potential mechanisms of
SKP2i, it is the increase of BECN1-directed autophagy that reduces
MERS-CoV multiplication. If this is correct, other ways of
enhancing BECN1′s effect on autophagy should elicit similar
effects. Therefore, we used two recently introduced tools to
enhance BECN1 function in autophagy: the BH3 mimetic ABT-
737 and a BECN1-derived peptide53,54. These compounds, in
contrast to SKP2i, do not change the levels of BECN1, but increase
autophagy by redirecting BECN1 function towards the autophagy
pathway, which we conﬁrmed in VeroB4 cells (Supplementary
Fig. 7b–d, g). Enhanced autophagy was indicated by the increase of
LC3B-II/I (Supplementary Fig. 7e, g) and the reduction of P62
(Supplementary Fig. 7f, g). This was paralleled by inhibition of
MERS-CoV replication by up to 60-fold in the case of the BECN1-
peptide (TAT-B) (Figure Supplementary Fig. 7h) and up to 10-fold
in the case of ABT-737 at 48h p.i. (Supplementary Fig. 7i). These
results are in accordance with the notion that increasing BECN1
c
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Fig. 5 SKP2 inhibitors enhance BECN1 protein stability and autophagy.
a, b Evaluation of small compounds inhibiting SKP2. HEK293 cells were
exposed to known SKP2 inhibitors for 24 h, followed by additional exposure
to cycloheximide (CHX, 30 µg mL−1) for the times as indicated or vehicle
(a). b HEK293 cells were transfected with Halo-tagged BECN1 expressing
plasmid and exposed to known SKP2 inhibitors and halogenated dye (100
nM, R110Direct) overnight. Cells were transferred to medium without dye
and harvested after the indicated times. Labelled BECN1 was determined
and quantiﬁed. c HEK293 cells were transfected with control vector (−) or
plasmids expressing BECN1-Flag, HA-ubiquitin and myc-SKP2. Cells were
exposed to known SKP2 inhibitors (C1, 3 µM; SMER3, 5 µM; SMIP004,
10 µM) for 24 h, BECN1 was precipitated from cell extracts and its
ubiquitination and levels were determined by western blotting. d SKP2
inhibitors impact long-lived proteins. HEK293 cells were metabolically
labelled with [14C]-valine overnight, exposed to the indicated drugs or
starvation (HBSS=Hank’s balanced salt solution) and the degradation of
proteins was determined 4 h after withdrawal of [14C]-valine completed
media. The autophagy inhibitor 3-MA (10mM) was used as control. e, f
Assessment of autophagy markers upon exposure to SKP2 inhibitors.
VeroB4 cells were exposed to the indicated drugs or vehicle and the levels
of P62 and LC3B-II/I were determined by western blotting (e). The most
efﬁcient drug, SMIP004, was analyzed in the ﬂux assay with baﬁlomycin A1
(BafA1; f). In all panels, error bars denote the standard error of the mean,
derived from n= 3 biologically independent experiments. WCE=whole cell
extract. *,$p < 0.05, **,$$p < 0.01, ***,$$$p < 0.001 (two-way ANOVAs,
details in Supplementary Table 1). In d, *labels refer to the effects of 3-MA,
$labels to the drug effects in comparison to vehicle. Source data and blot
collections are provided as a Source Data ﬁle.
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acts through enhancing autophagy as the relevant mechanism for
the antiviral effects of SKP2 in vitro.
To determine whether SKP2i relieves the antagonistic effects of
MERS-CoV infection on autophagy, we performed ﬂux assays
using either BafA1 or the tandem-labelled LC3B. While BafA1
did not change LC3B lipidation in infected cells as evidenced by
constant levels of LC3B-II/I in the absence of SKP2i (as before,
Fig. 6g gray bars), it increased LC3B-II/I in the presence of SKP2i
(Supplementary Fig. 7j). The ﬂuorescence-based assay revealed
that SKP2i enhanced the number of AP while decreasing the
number of AL (Fig. 8b, c). Furthermore, SKP2i enhanced ATG14
oligomerization (Fig. 8d, e) and the interaction of autophagic
SNARE complex proteins (STX17 with VAMP8 or SNAP29), in
MERS-CoV infected cells (Fig. 8f), thereby counteracting the
effect of MERS-CoV (see above, Fig. 6h). Thus, SKP2i inhibits
MERS-CoV production, most likely by enhancing BECN1 levels,
which might also account for its effect on late steps of
autophagy55. Since very little interaction between BECN1 and
STX17 was detected using immunoprecipitation, this effect of
BECN1 may require interaction with ATG146.
These results encouraged us to test other potential inhibitors of
SKP2. Autophagy-inducing, FDA-approved drugs and drugs
from clinical trials were of particular interest as these could
become more readily available for treatment in humans. Of note,
valinomycin (VAL), which has been shown to target SARS-CoV
in vitro45,56, is also known to act as an SKP2 inhibitor44.
Of the chosen drugs (Table S3), niclosamide (NIC) and VAL
were efﬁcient in enhancing BECN1, LC3B-II/I and autophagic
Co
MERS-CoV 
infected
a
e
kDa
DSS
MERS-CoV
ATG14
oligomers
ATG14
monomers
+
++
––
–
+
–
440
280
200
116
66
b
Ab
BECN1 
BECN1 
BE
CN
1 
(U
b-K
48
)n
W
CE
BE
CN
1-
IP
MERS-CoV– – +
BECN1– + +
ACTIN 
Ub
-K
48
 b
in
di
ng
 to
 B
EC
N1
0.0
0.5
1.0
1.5
2.5 Ub-K48
BECN1-IP:
*
2.0
0.0
0.5
1.0
1.5
Pr
ot
ei
n 
le
ve
l
f
+–
***
ATG14
Mono
Oligo
MERS-
CoV
g
0.0
1.0
2.0
3.0
BafA1
LC3B-II/I 
***
***
+ +– –
R
el
at
iv
e 
le
ve
ls
ACTIN
LC3B-I
LC3B-II
BafA1
MERS-CoV
–
+
+
+
–
–
+
–
Co
MERS-CoV 
infected
h
W
CE
El
ua
te
STX17
SNAP29
VAMP8
SNAP29
VAMP8
STX17
MERS-CoV– – + +
(+STX17)
(+STX17)
Pr
ot
ei
n 
bi
nd
in
g 
to
 S
TX
17
+–
*
SNAP29
VAMP8
0.0
0.5
1.0
1.5
2.5
MERS-
CoV
**
2.0
0
10
20
30
40 LC3B-mRFP/EGFP 
Ve
si
cl
es
 p
er
 c
el
l
MERS
CoV
AL
AP
– +
###
*
c
d LC3B-mRFP-EGFP:
Co
nt
ro
l
Merged
M
ER
S-
Co
V
EGFPmRFP
BECN1
MERS
– – + +
ACTIN
pSKP2
SKP2
(S72)
CoV
55
40
35
kDa
40
40
55
55
100
130
kDa
40
10
kDa
35
10
kDa
35
55
40
Fig. 6 MERS-CoV blocks autophagic ﬂux. a MERS-CoV decreases BECN1 and increases pSKP2. VeroB4 cells were infected with MERS-CoV (MOI=0.001)
or mock-infected and harvested 48 h later. Representative western blots are shown, quantiﬁcation in Supplementary Fig. 3a, b. b MERS-CoV increases K48-
linked poly-ubiquitination of BECN1. BECN1 was immune-precipitated from cell extracts 48 h p.i. and its ubiquitination determined by a ubiquitin K48 linkage
speciﬁc antibody. c, dMERS-CoV blocks fusion of AP with lysosomes. VeroB4 cells were transfected with tandem ﬂuorescent-tagged LC3B (mRFP and EGFP)
and infected with MERS-CoV (MOI= 0.001). Twenty-four hours later, cells were ﬁxed and analyzed for ﬂuorescence. Vesicles with both green and red
ﬂuorescence (autophagosomes, AP) and with red ﬂuorescence only (autolysosomes, AL) were counted. d, representative images, scale bar 25 µm. e, fMERS-
CoV decreases ATG14 oligomerization. VeroB4 cells were infected with MERS-CoV (MOI= 0.001), cross-linked with disuccinimidyl suberate (DSS, 75 µM)
48 h p.i. for 30min and harvested. ATG14 homo-oligomerization was examined after western blotting (ProteinSimple). g MERS-CoV decreases autophagic
ﬂux. VeroB4 cells were infected with MERS-CoV (MOI=0.001) and incubated with baﬁlomycin A1 (BafA1, 0.1 µM) for 2 h before samples were taken at 48 h
p.i.. The ratios of LC3B-II/I were determined by western blotting. h MERS-CoV affects SNARE protein interactions. VeroB4 cells were infected with MERS-
CoV (MOI=0.001), cross-linked with disuccinimidyl suberate (DSS, 75 µM) 48 h p.i. for 30min and harvested. The SNARE complex protein STX17 was
immunoprecipitated and the eluate was probed for interacting VAMP8 and SNAP29 by western blotting (the quantiﬁcation represents the bands detected at
the combined molecular weights of the cross-linked proteins, i.e. STX17+VAMP8 and STX17+ SNAP29). In all panels, error bars denote the standard error
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ﬂux (Fig. 9a, Supplementary Fig. 8a, b, Supplementary Table 3)
and comparable to SKP2i (see Fig. 5e, f, Supplementary Fig. 2e, f).
NIC and VAL reduced MERS-CoV multiplication by up to 1000-
fold at 48 h p.i. (Fig. 9b, Supplementary Fig. 9a–c). Thus, NIC and
VAL were characterized further. Both drugs enhanced ATG14
oligomerization about twofold (Supplementary Fig. 9d, e) and
increased the number of autolysosomes more than twofold
(Supplementary Fig. 9f, g). NIC also affected the autophagic ﬂux
in the infected cells similar to SKP2i (Supplementary Fig. 9h, i).
Therefore, these three compounds were tested for their dose-
effect relationship in a MERS-CoV infection experiment. All
compounds showed high efﬁcacy, (ImaxSKP2i= 28,000 fold,
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ImaxNIC= 23,000 fold and ImaxVAL= 93,000 fold; Fig. 9c, Supple-
mentary Fig. 10) and moderate to high potency (IC50SKP2i= 9
µM, IC50NIC= 0.32 µM and IC50VAL= 84 nM).
Discussion
The present work reveals BECN1 as a target of the E3 ligase
SKP237,38,46. SKP2 executes K48-linked ubiquitination at K402 of
BECN1, resulting in proteasomal degradation. This action of
SKP2 is counteracted by FKBP51 that regulates SKP2 phos-
phorylation through forming regulatory complexes with AKT1
and PHLPP. Inhibition of SKP2 increases BECN1 levels, enhances
the assembly of lysosomal SNARE proteins and autophagy, and
efﬁciently reduces the replication of MERS-CoV (Fig. 9d).
FKBP51 is a pivotal element of molecular feedback loops of the
cellular and physiological stress reaction. It increasingly emerges
as a scaffolder that chaperones various regulatory protein inter-
actions3. Here, FKBP51 appears to recruit SKP2 in its inactive
form to BECN1, probably by virtue of its interaction with the
kinase AKT1 and the phosphatase PHLPP. Similarly, FKBP51-
directed protein interactions increase BECN1 phosphorylation2,
decrease phosphorylation and activity of AKT131. Thus, FKBP51
impacts BECN1 at least via two mechanisms, phosphorylation of
BECN1 itself2 and of its regulatory E3 ligase SKP2. Both
mechanisms involve AKT1, which exhibits yet another way of
inﬂuencing BECN1 by phosphorylating USP14, which removes
K63-linked ubiquitins from BECN157.
In addition to K48-linked poly-ubiquitination by SKP2,
BECN1 undergoes ubiquitination also by other E3 ligases, at
different sites, and with different types of poly-ubiquitination
linkage12,58,59. NEDD4 produces both K63- and K11-linkages at
yet to be determined sites of BECN19. Decoration of BECN1 with
c
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the non-canonical K11-linked ubiquitins by NEDD4 leads to its
proteasomal degradation60. K63-linked ubiquitination of the BH3
domain of BECN1 at K117 by TRAF6 enhances autophagy,
possibly by reducing the interaction of BECN1 with BCL235.
AMBRA1 is another positive regulator of autophagy61. As a
substrate receptor for the DDB1-cullin4 E3 ligase complex62, it
forms K63-linked ubiquitin chains at K437 of BECN1, enhances
the association between BECN1 and Vps34/PI3K3C, and thus
stimulates the activity of this autophagy promoting lipid kinase63.
In sum, BECN1 activity is regulated by ubiquitination in multiple
ways, both stimulatory and inhibitory.
Very recently, the polyQ domain protein ataxin 3 has been
shown to interact with BECN1 and to remove K48-linked poly-
ubiquitin, an activity that is competitively inhibited by longer
polyQ mutation in a disease protein64. Together with the here-
presented discovery of SKP2 as K48-linking E3 ligase of BECN1,
this points to the intriguing possibility that inhibiting SKP2 using
small molecule inhibitors might counteract deleterious effects of
soluble proteins with polyQ expansions that are held responsible
for causing neurodegenerative diseases such as Huntington's
disease and ataxin 3 in spinocerebellar ataxia64.
Due to the tremendous variability of viral proteins, there is huge
interest in host cell-encoded pathways that could be exploited for
ﬁghting viral infection. The present study as well as earlier work
suggest autophagy as a pivotal component of virus-host interaction
and potential broad-range antiviral target13,52. For MERS-CoV
replication, it remains to be elucidated whether blocking basal
autophagy is mandatory or only auxiliary; nevertheless, the virus
encodes at least three proteins that limit autophagy when expressed
ectopically, NSP6, p4b and p5. Although the detailed molecular
mechanisms are yet to be analysed, MERS-CoV NSP6 may also
play a role in inhibiting the expansion of autophagosomes as
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Source data are provided as a Source Data ﬁle.
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shown for other betacoronaviruses48. MERS-CoV p4b has phos-
phodiesterase function inhibiting the activation of RNAse L, which
itself can activate autophagy65. MERS-CoV p5 is located in the
endoplasmic reticulum-Golgi intermediate compartment51 and
was shown to inhibit IFN-beta induction66, which may constitute
another link to autophagy67.
Deletion of p4b or p5 resulted in reduced MERS-CoV growth.
These results differ from previous observations, which may be
related to different cell lines and cDNA clone construction
strategies68,69. In addition, we used a very low MOI and a type I
IFN-deﬁcient cell line (VeroB4), which allows to determine minor
growth differences. The absence of p4b and p5 during MERS-CoV
replication may also result in lower LC3B levels compared to
MERS-CoV wildtype-infected but also to the mock-infected con-
trol cells. This points to a more complex interaction between virus
replication and autophagy; p4b and p5 may counteract a response
of the host to viral infection, but the functional relevance of their
link to autophagy requires further investigation. Apparently, sev-
eral CoV proteins collaborate to reprogram the membrane trafﬁc
in the cell for DMV formation serving as compartments of viral
genome replication and transcription18,24. Since autophagy is
tightly linked to intracellular membrane trafﬁc and turnover, it
appears possible that MERS-CoV blocks autophagy not only to
evade degradation but also to improve membrane availability.
It appears that most of the potential treatments arising from
other observations of reduction of viral replication upon autop-
hagy stimulation are not easily applicable in vivo because of side
effects and inefﬁcient peptide delivery70. Examples are rapamycin
and vitamin D which restricted the replication of HIV in primary
human macrophages71, and the autophagy-inducing BECN1-
derived peptide which limited the replication of a number of
viruses in vitro53. From the present results, therapeutic induction
of autophagy by inhibition of SKP2 emerges as a promising
approach. We should note that all the substances tested here have
or may have additional targets. While we cannot exclude the
possibility that for each of the compounds it is this additional
target that is responsible for the antiviral effect, we consider this
scenario as less likely; this assessment is also based on the
observation of the antiviral effects of compounds targeting
BECN1, which we establish here as client of SKP2. Nevertheless,
future experiments should assess the effect of these drugs in
autophagy-defective cells such as the Atg5 knockout cells.
It further remains to be investigated whether inhibiting SKP2
will affect all autophagy-sensitive viruses. SINV, which was not
overtly inﬂuenced by Atg5 knockout despite indications of
degradation of viral components through autophagy72, reacted
modestly to SKP2i. The reason for this is unknown; it may relate
to the involvement of other immune pathways inﬂuencing SINV,
for example the JAK/STAT pathway73 or stress granule forma-
tion74, or to autophagy functioning in the absence of Atg575.
FDA-approved drugs known to act as SKP2 inhibitors are
available44. We show that some of these drugs are effective in
reducing MERS-CoV replication in vitro, for example niclosa-
mide and pyrvinium pamoate. Even though there are reports of
low absorption of these drugs76, others found considerable
absorption and serum levels of niclosamide reached 1-20 µM77,
concentrations we show here to efﬁciently limit MERS-CoV
replication. In addition, inhalable formulations of niclosamide
have been developed78. SKP2-targeting compounds also may
have potential against other infections and other clinical condi-
tions that are inﬂuenced by autophagy induction79,80.
Methods
Chemicals. The following chemicals were used for treatment of cells: BafA1 (Alfa
Aeser, J61835), 17-AAG (Sigma-Aldrich, A8476), 6-AN (Sigma-Aldrich, A68203),
AMI (Sigma-Aldrich, 1019701), BRO (Sigma-Aldrich, 1076501), CEL (Sigma-
Aldrich, PZ0008), CLO (Sigma-Aldrich, C7291), ETO (Sigma-Aldrich, E1383),
(MET (Sigma-Aldrich, M0605000), PAR (Sigma-Aldrich, P9623), RAP (Tocris,
1292), SMER3 (Tocris, 4375), ABT-737 (Selleckchem, S10002), Tat-B (Anaspec,
AS65467), Tat-scr. (Anaspec, AS65468), GOS (Sigma-Aldrich, G8761), HAL (Tocris,
0931), MIN (Sigma-Aldrich, M9511), NIC (Sigma-Aldrich, N3510), PIM (Sigma-
Aldrich, P1793), PRT (Tocris, 0610), PER (Sigma-Aldrich, SML0120), PEP (Sigma-
Aldrich, P6402), PYR (Sigma-Aldrich, 1592001), RAS (Sigma-Aldrich, SML0124),
SEC (Sigma-Aldrich, SML0055), SAL (Sigma-Aldrich, S4526), TAM (Sigma-Aldrich,
T5648), TOP (Tocris, 4562), VAL (Sigma-Aldrich, V0627), PHLPPi NSC117079
(GlixxLabs, GLXC-03994), C14-Valine (Perkin Elmer, NEC291EU050UC), Akti X
(Cayman Chemical, 14863) MK-2206 HCl (Cayman Chemical, 11593).
Co-Immunoprecipitation (CoIP) with crosslinker. CoIP of endogenous STX17 or
BECN1 were performed in VeroB4 cells. The PBS-washed cell pellet was incubated
with 75 µM DSS (disuccinimidyl subernate, Thermo Fisher Scientiﬁc, 21655) or
corresponding vehicle (DMSO) in PBS. Crosslinking was performed for 30 min at
room temperature followed by 2 h at 4 °C while rotating. After washing with PBS,
crosslinking was quenched in tris-buffered saline (pH 7.0) for 20 min at 4 °C. Cells
were lysed in CoIP-buffer containing 20 mM Tris-HCl pH 8.0, 100 mM NaCl,
1 mM EDTA, 0.5% IGEPAL CA-630 complemented with protease inhibitor
cocktail (Sigma, P2714). This was followed by incubation on an overhead shaker
for 20 min at 4 °C. 1.2 mg of lysate was incubated with 2.5 µg STX17 or BECN1
antibody overnight at 4 °C. 20 µl of BSA-blocked Protein G Dynabeads (Invitrogen,
100–03D) were added to the lysate–antibody mix followed by 3 h incubation at
4 °C. The beads were washed three times with PBS and protein-antibody complexes
were eluted by boiling for 5 min at 95 °C in Laemmli loading buffer. Fifteen
microgram of the cell lysates or 5 µl of the immunoprecipitates were separated by
SDS-PAGE.
Toxicity assays. LDH assay. To assess membrane disruption and cell death the
release of lactate dehydrogenase (LDH) into the growth medium of HEK293 or
VeroB4 cells was measured. The assay (LDH cytotoxicity detection system) was
carried out according to the manufacturer’s protocol (Clontech, Mountain View, CA,
USA). As positive control 0.02% Triton X-100 was added to the medium 1–2 h prior
performing the assay; empty wells were used with medium only, as negative control.
MTT assay. HEK293 or VeroB4 cells were incubated in the presence of 0.5 mg
mL−1 tetrazole 3-(4,5-dimethylthiazol-2-yl-)-2,5-diphenyltetrazolium bromide
(MTT) for 4 h at 37 °C and 5% CO2. Read-out of MTT assay was carried out as
described previously81.
Western blot analysis. Protein extracts were obtained by lysing cells in RIPA buffer
(150mM NaCl, 1% IGEPAL CA-630, 0.5% Sodium deoxycholate, 0.1% SDS 50mM
Tris (pH8.0)) freshly supplemented with protease inhibitor (Merck Millipore,
Darmstadt, Germany), benzonase (Merck Millipore), 5 mM DTT (Sigma Aldrich,
Munich, Germany), and phosphatase inhibitor (Roche, Penzberg, Germany) inhi-
bitor cocktail. Proteins were separated by SDS-PAGE and electro-transferred onto
nitrocellulose membranes. Blots were placed in Tris-buffered saline, supplemented
with 0.05% Tween (Sigma Aldrich) and 5% non-fat milk for 1 h at room temperature
and then incubated with primary antibody (diluted in TBS/0.05% Tween) overnight
at 4 °C. The following primary antibodies were used: Actin (1:5000, Santa Cruz
Biotechnologies, sc-1616), Beclin-1 (1:1000, Cell Signaling Technology, #3738), K48-
linkage Speciﬁc Polyubiquitin (D9D5) Rabbit mAb (Cell Signaling #8081, 1:500),
PI3K3C (1:1000, Cell Signaling Technology, #4263), LC3-B (1:1000, Cell Signaling
Technology, #3868), SQSTM1/p62 (1:1000, Cell Signaling Technology, #5114),
VAMP8 (1:1000, Cell Signaling Technology, #13060), Atg14 (1:1000, Cell Signaling
Technology, #5504), STX17 (1:1000, Sigma Aldrich, SAB001204), SNAP29 (1:1000,
Sigma Aldrich, SAB2107406), PHLPP1 (1:1000, Millipore, 07–141). The antibody
recognizing pSKP2 (S72) was a kind gift from Cell Signaling Technology®.
Subsequently, blots were washed and probed with the respective horseradish
peroxidase- or ﬂuorophore-conjugated secondary antibody for 1 h at room
temperature. The immuno-reactive bands were visualized either using ECL
detection reagent (Millipore, Billerica, MA, USA) or directly by excitation of the
respective ﬂuorophore. Determination of the band intensities were performed with
BioRad, ChemiDoc MP.
In the case of ATG14 oligomerization, lysates were analyzed by capillary
electrophoresis on Wes™ (ProteinSimple) using the 60–440 kDa cartridges.
In general, protein quantiﬁcation was performed by normalization to the
intensity of Actin, which was determined on the same membrane. For
quantiﬁcation of lipidated LC3B, the intensity of LC3B-II was always referred to
the signal intensity of the corresponding LC3B-I, following the guidelines for the
determination of autophagy43.
RIPA lysis of MERS-CoV infected VeroB4 cells. Whole cell lysates were pre-
pared with RIPA lysis buffer containing 150 mM NaCl, 1% IGEPAL CA-630, 0.5%
sodium deoxycholate, 0.1% SDS and 50 mM Tris (pH 8.0). 1% proteinase inhibitor
cocktail III [Calbiochem], 0.1% benzonase [Novagen], 0.5% dithiothreitol [0.1 mM]
and 1% phosphataseinhibitor [PhosphoSTOP, Roche] were freshly added. For cell
lysis, supernatant was discarded and cells were carefully rinsed 3x with pre-cooled
1x PBS. 500 µl of pre-cooled 1x PBS was added and cells were scraped off and
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transferred to a microcentrifuge tube. Cells were pelleted by centrifugation at 4 °C
and 300 × g for 5 min The supernatant was removed carefully and cells were
resuspended in 100 µl RIPA lysis buffer and incubated for 20 min at 4 °C for
efﬁcient lysis. Then, SDS loading buffer (4x NuPAGE LDS, ThermoFisher Scien-
tiﬁc) was added and samples were boiled at 95 °C for 10 min Samples were stored
at −20 °C and processed as indicated in the respective sections.
Cells. VeroB4 (DSMZ [German Collection of Microorganisms and Cell Cultures]
number-ACC33) were cultivated in Dulbecco’s Modiﬁed Eagles Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, 1%
non-essential amino acids, 1% L-glutamine and 1% sodium pyruvate at 37 °C and
5% CO2. HEK293 cells (ATCC, Manassas, VA, USA CRL-1573) were cultivated in
DMEM supplemented with 10% FBS, 1% penicillin/streptomycin and 1% sodium
pyruvate at 37 °C and 5% CO2. For transfection HEK293 and VeroB4 were detached
and resuspended in 100 µL (50mM HEPES pH 7.3, 90mM NaCl, 5 mM KCl,
0.15 mM CaCl2) transfected using the Nucleofector II system (program # T020).
Generation of Atg5 KO VeroB4. Vero B4 were plated in 6-well plates at a cell
density of 5 × 105/well in VeroB4 medium and transfected with lipofectamine 3000
according to the manufacturer’s protocol. For the Atg5 knock-out, the pSpCas9
BB-2A-Puro (PX459) V2.0 plasmid containing Atg5-targeting gRNA (sequence: 5′-
TATCCCCTTTAGAATATATC-3′) purchased from GenScript was used. Forty-
eight after transfection, 10 μg mL−1 puromycin (InVivoGen, ant-pr-1) was added
to the medium. After 48 h, the medium was changed to puromycin-free VeroB4
medium and, another 48 h later, cells were sorted into a 96-well plate at a density of
one cell per well using the BD FACSMelody cell sorter (BD Biosciences). Cells were
maintained in conditioned medium for 1 week until a colony was formed from a
single cell. All the colonies were then trypsinized and expanded individually. Atg5
knockout was examined for each clone by western blot analysis using anti-Atg5
purchased from Santa Cruz (sc-133158).
Virus infection. For virus infection, cells were seeded in a concentration of 3.5 × 105
cells mL−1. After 24 h, virus stocks were diluted in serum-free medium according to
the desired MOI. For virus adsorption, 1 ml (six-well) virus master mix was added to
the cells and incubated for 1 h at 37 °C. When comparing to non-infected cells, heat-
inactivated (95 °C, 10min) virus was used (mock control). After 1 h, the virus
dilutions were removed and the wells were washed twice with 1x PBS and reﬁlled
with DMEM (supplemented as described above). Samples were taken at the indi-
cated time points. All virus infection experiments were conducted under biosafety
level 3 conditions with enhanced respiratory personal protection equipment.
For all SINV infection experiments strain LEIV-Ast03 was used. SINV
infections were done using VeroB4 cells applying an MOI= 0.0001 for 16 and 24 h.
The SKP2-inhibitor SMIP004 (SKP2i) was applied at a concentration of 10 µM.
Real-time RT-PCR assay. Genome equivalents were determined by real-time RT-
PCR. Therefore, 75 µl of cell supernatant was lysed in RAV1 lysis buffer (Macherey
& Nagel) and heated to 70 °C for 10 min for virus inactivation. Then, viral RNA
was extracted according to the manufacturer’s instructions. Real-time RT-PCR
assays were performed as before82. More speciﬁcally, the upE assay was applied for
the detection of MERS-CoV genome equivalents, the ORF1b assay was used for the
detection of MERS-del4b and MERS-del5 genome equivalents. Primers were upE-
Fwd (5′-GCAACGCGCGATTCAGTT-3′), upE-Rev (5′-GCCTCTACACGGGAC
CCA TA-3′) and 200 nM of probe upE-Prb (6-carboxyﬂuorescein [FAM])-CTCTT
CACATAA TCGCCCCGAGCTCG-6-carboxy-N,N,N,N´-tetramethylrhodamine
[TAMRA]) as well as ORF1b-Fwd (5′-TTCGATGTTGAGGGTGCTCAT-3′),
ORF1b-Rev (TCACACCAGTTGA AAATCCTAATTG) and probe ORF1b-Prb
(6-carboxyﬂuorescein [FAM])-CCCGTAAT G CATGTGGCACCAATGT-6-car
boxy-N,N,N,N´-tetramethylrhodamine [TAMRA]). For quantiﬁcation of BECN1-
mRNA, primers (forward 5′-CAAGATCCTGGA-3′, reverse 5′-CCGTGTCA-3′)
were used as described in83.
Plaque assay. SINV infectious particles were quantiﬁed by plaque titration on
VeroB4 cells as previously described84 with minor modiﬁcations. Brieﬂy, VeroB4
monolayers were seeded in 24-well plates, incubated with SINV-containing cell
culture supernatants and overlaid with 1.2% Avicel in MEM containing 2% FCS
and 1% penicillin-streptomycin. After 16 h, 24 h or 72 h, plaques were ﬁxated and
visualized by staining with crystal violet and counted.
Plasmids and construction of MERS-CoV cDNA clones. For heterologous
expression, nsp4 and nsp6 were PCR ampliﬁed from MERS-CoV cDNA and cloned
into the eukaryotic expression plasmid pCAGGS along with a C-terminal FLAG tag
(MERS-nsp4-F: 5′-AGAGAATTCGCCACCATGGCTCCTACATGGTTTAATG
C-3′, MERS-nsp4-R: 5′-TCTGCGGCCGCCTATCACTTGTCATCGTCGTCCTTGT
AGTCGCC GGCTTGCAACACGCCAGAGGTTATGC-3′, MERS-nsp6-F: 5′-AGAG
AATTCGCCACC ATGAGTGGTGTGAGAAAAGTTACATATGG-3′, MERS-nsp6-
R: 5′-TCTGCGGCCGCC TATCACTTGTCATCGTCGTCCTTGTAGTCGCCGGC
CTGCATAGCAGCAACCTTTAA CAAGG-3′). Construction of the plasmids
expressing the accessory open reading frames (ORFs) 3, 4a, 4b, and 5 was previously
described51.
Construction of a MERS-CoV cDNA clone lacking accessory ORFs: The
accessory ORFs (ORF4b or ORF5) were deleted using a two-step markerless Red
Recombination system as extensively described85,86. Brieﬂy, in a ﬁrst step a
kanamycin resistance gene was ampliﬁed by an overhang extension PCR from the
pEP-KanS vector (kindly provided by K. Tischer and K. Osterrieder) with primers
containing homologous MERS-CoV recombination sites, the desired mutation and
an I-SceI restriction site (MERS-delta4b-ABC-Kana-F: 5′-ATT CGCGCAAAGCG
AGGAAGAGGAGCCATTCTCAACTAATGATGTTGTCTCCATACGG TCTTT
AGGGATAACAGGGTAATCGATTT-3′ and MERS-delta4b-BCD-Kana-R: 5′-TT
GTTTATTACCCTGATTGGAAGACCGTATGGAGACAACATCATTAGTTGG
AGAATG GCTCCTGCCAGTGTTACAACCAATTAACC-3′; MERS-delORF5_
Kana-F: 5′-TTCTTA TCCCATTTTACATCATCCAGGATTTTAACGAACTGCA
GCTCTGCGCTACTATGGTA GGGATAACAGGGTAATCGATTT-3′ and
MERS-delORF5_Kana-R: 5′-GATTAGCCTC TACACGGGACCCATAGTAGCG
CAGAGCTGCAGTTCGTTAAAATCCTGGATGCCAG TGTTACAACCAATTA
ACC-3′). We would like to point out that this design preserves the regulatory sites
of ORF5, in contrast to a previous approach69. Our rationale was to preserve an
equal number of subgenomic mRNAs. E. coli GS1783 cells (kindly provided by K.
Tischer and K. Osterrieder) containing the MERS-CoV cDNA clone were
transfected with the PCR product in order to induce the recombination of the
transfer construct into the MERS-CoV backbone. In a second step, the kanamycin
selection marker was excised by an inducible in vivo I-SceI cleavage and the second
Red recombination event. Rescue and stock production of the recombinant viruses
were performed as described elsewhere85.
The following expression constructs were used for experiments performed in
cultured cells: pRK5-FKBP51-Flag, pRK5-FKBP52-Flag2,87, pRK5-HA-Ubiquitin-
WT (Addgene.org, #17608), pRK5-HA-Ubiquitin-KO (Addgene.org, #17603),
pRK5-HA-Ubiquitin-K11 (Addgene.org, #22901), pRK5-HA-Ubiquitin-K29R
(Addgene.org, #17602), pRK5-HA-Ubiquitin-K48 (Addgene.org, #17605), pRK5-
HA-Ubiquitin-K63 (Addgene.org, #17606), Beclin1-HT (Promega, FHC08488),
FLAG-HA-USP18 (Addgene.org, #22572), FLAG-HA-USP36 (Addgene.org,
#22579), pcDNA3-myc-SKP2 (Addgene.org, #19947), FLAG-TRAF6-wt (Addgene.
org, #21624), pcDNA4-Beclin1-HA (FL) (Addgene.org, #24388). The
phosphomimetic and phospho-null mutants S72D/S75D and S72A of SKP2 were
kind gifts from the authors of41. Transfection of the constructs FLAG-HA-USP18
and and FLAG-HA-USP36 each led to the appearance of another band at higher
molecular weight in western blots. Irrespective of the exact nature of these bands,
speciﬁc co-precipitation with FKBP51 was only observable for the bands at the
predicted molecular weight (Fig. 1a); these were absent in coprecipitations of
BECN1 (Fig. 1b). Figure 1a, b display the bands at the predicted molecular weight.
Skp2 knockdown. HEK293 cells were electroporated as described above with skp2-
siRNA (sense 5′-GUCGGUGCUAUGAUAAUTT-3′; anti-sense 5′-AUUAUAUC
AUCGCACCGACTT-3′) or control siRNA (sense 5′-UUCUCCGAACGUGUCA
CGUTT-3′; anti-sense 5′-ACGUGACACGUUCGGAGAATT-3′) and harvested
after 48 h. Primers were purchased from Biomol (Hamburg, Germany).
Autophagic ﬂux. To determine the effect of drug treatment or MERS-CoV infection
on autophagic ﬂux, either BafA1 (Alfa Aeser, J61835), a speciﬁc inhibitor of vacuolar
H+-ATPases interfering with lysosome acidiﬁcation and thereby degradation of
autophagosome cargo, was used or transfection with a plasmid (ptfLC3, Addgene.
org, #21074) that expresses LC3 tagged with both GFP (inactivated in autolyso-
somes) and mRFP (resists inactivation in autolysosomes)88, following the recently
updated guidelines for monitoring autophagy43. Transfection in Vero4B cells was
performed using Fugene transfection reagent (Promega), followed by MERS-CoV
infection (MOI= 1) and drug treatment the next day. Cells were ﬁxed (1% PFA for
1 h) 1 day later and analyzed by laser scanning microscopy (Leica Confocal Sp8).
Vesicles were counted by an experimenter blind to the conditions.
Long-Lived protein degradation assay. Experiments were performed as described
by Klionsky et al.43. Cells were incubated with valine[14C] overnight, chased in
fresh media with excess valine overnight, and then incubated 4 h with complete
medium or starvation media (HBSS/EBSS+ 10 mM HEPES, Starv). To check that
protein degradation measured was due to autophagic processes, experiments were
also performed in the presence of 3-MA (10 mM, which is typically used for the
inhibition of autophagy89). LLP degradation with SKP2-KD was monitored 48 h
after transfection.
Inhibition of translation by cycloheximide (CHX). HEK293 cells were incubated
with 20 µgmL−1 CHX. MG132 (10 µM), 3.5 µg expression construct for FKBP51-
Flag, empty vector pRK5 SV40 MCS2, TRAF6-Flag (Addgene.org, #21624), SKP2-
MYC (Addgene.org, #19947) was used for stimulation or transfection of
HEK293 cells.
Pulse-Chase-Assay using Halo®-tagged BECN1. HEK293 cell were transfected
with 5 µg BECN1-HT expression construct. The pulse-chase assay was performed
according to manufacturer’s manual using R110Direct as halogenated ﬂuorophore
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(100 nM, R110Direct, #G3221, Promega) over-night (pulse), followed by switching
the cells to medium without dye (chase).
Determination of IC50. To estimate the maximal viral inhibition (Imax) and the
drug concentration achieving viral inhibition halfway between baseline and max-
imum (IC50), we ﬁrst normalized the dose-response curves for each drug by
dividing by cell viability, and we then ﬁtted the normalized viral inhibition curves
to a sigmoid curve using the Sigmoid and Nonlinear Least Squares functions in R
version 3.1.0 (http://www.R-project.org/) as previously described (http://kyrcha.
info/2012/07/08/tutorials-ﬁtting-a-sigmoid-function-in-r/). Based on the sigmoid-
ﬁtted curves, we then determined numerically the Imax and IC50.
Flow cytometry. Cells were washed in PBS and ﬁxed with cold ethanol (70%) for
30 min at 4 °C. After washing with PBS cells were treated with ribonuclease A
(100 µg mL−1; Sigma Aldrich) and stained with Vybrant DyeCycle Orange
(Invitrogen, V35005) as described by the manufacturer’s manual. Cells were
analyzed with the FACSCalibur (BD Biosciences). Acquired data were analyzed
with FlowJo software (Tree Star).
Statistical analysis. When two groups were compared, the student’s t-test was
applied. For three or more group comparisons, one or two-way analysis of variance
(ANOVA) was performed, as appropriate, followed by Tukey’s or Bonferroni’s post
hoc test, as appropriate. All t-test t and p-values and ANOVA F and p-values are
reported in the legends to the Supplementary Figures; signiﬁcant results of the
contrast tests are further indicated by asterisks in the graphs. All statistical tests
were two-tailed and p < 0.05 was considered statistically signiﬁcant. For the com-
plete set of raw data, see the data source ﬁle.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Candidate ubiquitination sites on BECN1 were taken from the mUbiSiDa data base
(originally at http://202.195.183.4:8000/mUbiSiDa.php, now part of omicX at https://
omictools.com/mubisida-tool). The source data underlying Figs. 1, 2, 4–9, and
Supplementary Figs. 1–10 are provided as a Source Data ﬁle. All other data is available
from the authors upon request.
Received: 11 June 2018; Accepted: 14 November 2019;
References
1. Bento, C. F. et al. Mammalian autophagy: how does it work? Annu. Rev.
Biochem. 85, 685–713 (2016).
2. Gassen, N. C. et al. Association of FKBP51 with priming of autophagy
pathways and mediation of antidepressant treatment response: evidence in
cells, mice, and humans. PLoS. Med. 11, e1001755 (2014).
3. Rein, T. FK506 binding protein 51 integrates pathways of adaptation: FKBP51
shapes the reactivity to environmental change. Bioessays 38, 894–902 (2016).
4. Levine, B., Liu, R., Dong, X. & Zhong, Q. Beclin orthologs: integrative hubs of
cell signaling, membrane trafﬁcking, and physiology. Trends Cell Biol. 25,
533–544 (2015).
5. Itakura, E., Kishi, C., Inoue, K. & Mizushima, N. Beclin 1 forms two distinct
phosphatidylinositol 3-kinase complexes with mammalian Atg14 and
UVRAG. Mol. Biol. Cell 19, 5360–5372 (2008).
6. Diao, J. et al. ATG14 promotes membrane tethering and fusion of
autophagosomes to endolysosomes. Nature 520, 563–566 (2015).
7. Huang, W. et al. Crystal structure and biochemical analyses reveal Beclin 1 as
a novel membrane binding protein. Cell Res 22, 473–489 (2012).
8. Wang, R. C. et al. Akt-mediated regulation of autophagy and tumorigenesis
through Beclin 1 phosphorylation. Science 338, 956–959 (2012).
9. Reidick, C., El, M. F., Meyer, H. E., Stenmark, H. & Platta, H. W. Regulation of
the tumor-suppressor function of the class III phosphatidylinositol 3-kinase
complex by ubiquitin and SUMO. Cancers (Basel) 7, 1–29 (2014).
10. Jin, S. et al. USP19 modulates autophagy and antiviral immune responses by
deubiquitinating Beclin-1. EMBO J. 35, 866–880 (2016).
11. Liu, J. et al. Beclin1 controls the levels of p53 by regulating the
deubiquitination activity of USP10 and USP13. Cell 147, 223–234 (2011).
12. Boutouja, F., Brinkmeier, R., Mastalski, T., El, M. F. & Platta, H. W.
Regulation of the tumor-suppressor BECLIN 1 by distinct ubiquitination
cascades. Int J. Mol. Sci. 18, E2541 (2017).
13. Dong, X. & Levine, B. Autophagy and viruses: adversaries or allies? J. Innate.
Immun. 5, 480–493 (2013).
14. Knoops, K. et al. SARS-coronavirus replication is supported by a
reticulovesicular network of modiﬁed endoplasmic reticulum. PLoS. Biol. 6,
e226 (2008).
15. Cottam, E. M. et al. Coronavirus nsp6 proteins generate autophagosomes from
the endoplasmic reticulum via an omegasome intermediate. Autophagy 7,
1335–1347 (2011).
16. Prentice, E., Jerome, W. G., Yoshimori, T., Mizushima, N. & Denison, M. R.
Coronavirus replication complex formation utilizes components of cellular
autophagy. J. Biol. Chem. 279, 10136–10141 (2004).
17. Cong, Y., Verlhac, P. & Reggiori, F. The interaction between nidovirales and
autophagy components. Viruses 9, E182 (2017).
18. Lundin, A. et al. Targeting membrane-bound viral RNA synthesis reveals
potent inhibition of diverse coronaviruses including the middle East
respiratory syndrome virus. PLoS. Pathog. 10, e1004166 (2014).
19. Corman, V. M. et al. Viral shedding and antibody response in 37 patients with
middle east respiratory syndrome coronavirus infection. Clin. Infect. Dis. 62,
477–483 (2016).
20. Reusken, C. B. et al. Middle east respiratory syndrome coronavirus
neutralising serum antibodies in dromedary camels: a comparative serological
study. Lancet Infect. Dis. 13, 859–866 (2013).
21. Müller, M. A. et al. MERS coronavirus neutralizing antibodies in camels,
Eastern Africa, 1983–1997. Emerg. Infect. Dis. 20, 2093–2095 (2014).
22. Kindrachuk, J. et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR
signaling modulation for Middle East respiratory syndrome coronavirus
infection as identiﬁed by temporal kinome analysis. Antimicrob. Agents
Chemother. 59, 1088–1099 (2015).
23. Kim, Y. C. & Guan, K. L. mTOR: a pharmacologic target for autophagy
regulation. J. Clin. Invest 125, 25–32 (2015).
24. Gosert, R., Kanjanahaluethai, A., Egger, D., Bienz, K. & Baker, S. C. RNA
replication of mouse hepatitis virus takes place at double-membrane vesicles.
J. Virol. 76, 3697–3708 (2002).
25. Reggiori, F. et al. Coronaviruses Hijack the LC3-I-positive EDEMosomes, ER-
derived vesicles exporting short-lived ERAD regulators, for replication. Cell
Host. Microbe 7, 500–508 (2010).
26. Zhao, Z. et al. Coronavirus replication does not require the autophagy gene
ATG5. Autophagy 3, 581–585 (2007).
27. Guo, L. et al. Autophagy negatively regulates transmissible gastroenteritis
virus replication. Sci. Rep. 6, 23864 (2016).
28. Zhu, L., Mou, C., Yang, X., Lin, J. & Yang, Q. Mitophagy in TGEV infection
counteracts oxidative stress and apoptosis. Oncotarget 7, 27122–27141 (2016).
29. Storer, C. L., Dickey, C. A., Galigniana, M. D., Rein, T. & Cox, M. B. FKBP51
and FKBP52 in signaling and disease. Trends Endocrinol. Metab. 22, 481–490
(2011).
30. Los, G. V. & Wood, K. The HaloTag: a novel technology for cell imaging and
protein analysis. Methods Mol. Biol. 356, 195–208 (2007).
31. Pei, H. et al. FKBP51 affects cancer cell response to chemotherapy by
negatively regulating Akt. Cancer Cell 16, 259–266 (2009).
32. Gassen, N. C. et al. FKBP51 inhibits GSK3beta and augments the effects of
distinct psychotropic medications. Mol. Psychiatry 21, 277–289 (2016).
33. Gassen, N. C. et al. Chaperoning epigenetics: FKBP51 decreases the activity of
DNMT1 and mediates epigenetic effects of the antidepressant paroxetine. Sci.
Signal. 8, ra119 (2015).
34. Taipale, M. et al. A quantitative chaperone interaction network reveals the
architecture of cellular protein homeostasis pathways. Cell 158, 434–448
(2014).
35. Shi, C. S. & Kehrl, J. H. TRAF6 and A20 regulate lysine 63-linked
ubiquitination of Beclin-1 to control TLR4-induced autophagy. Sci. Signal. 3,
ra42 (2010).
36. Akiyama, T. et al. Mitochondria-nucleus shuttling FK506-binding protein 51
interacts with TRAF proteins and facilitates the RIG-I-like receptor-mediated
expression of type I IFN. PLoS. ONE 9, e95992 (2014).
37. Chen, Q. et al. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and
Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 111,
4690–4699 (2008).
38. Shin, H. J. et al. AMPK-SKP2-CARM1 signalling cascade in transcriptional
regulation of autophagy. Nature 534, 553–557 (2016).
39. Ikeda, F. & Dikic, I. Atypical ubiquitin chains: new molecular signals. ‘Protein
Modiﬁcations: Beyond the Usual Suspects' review series. EMBO Rep. 9,
536–542 (2008).
40. Chen, T. et al. mUbiSiDa: a comprehensive database for protein
ubiquitination sites in mammals. PLoS. ONE 9, e85744 (2014).
41. Gao, D. et al. Phosphorylation by Akt1 promotes cytoplasmic localization of
Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat. Cell Biol. 11,
397–408 (2009).
42. Sierecki, E., Sinko, W., McCammon, J. A. & Newton, A. C. Discovery of small
molecule inhibitors of the PH domain leucine-rich repeat protein phosphatase
(PHLPP) by chemical and virtual screening. J. Med. Chem. 53, 6899–6911
(2010).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13659-4
14 NATURE COMMUNICATIONS |         (2019) 10:5770 | https://doi.org/10.1038/s41467-019-13659-4 | www.nature.com/naturecommunications
43. Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for
monitoring autophagy (3rd edition). Autophagy 12, 1–222 (2016).
44. Rico-Bautista, E., Yang, C. C., Lu, L., Roth, G. P. & Wolf, D. A. Chemical
genetics approach to restoring p27Kip1 reveals novel compounds with
antiproliferative activity in prostate cancer cells. Bmc. Biol. 8, 153 (2010).
45. Wu, L. et al. Speciﬁc small molecule inhibitors of Skp2-mediated p27
degradation. Chem. Biol. 19, 1515–1524 (2012).
46. Aghajanyy, M. et al. Chemical genetics screen for enhancers of rapamycin
identiﬁes a speciﬁc inhibitor of an SCF family E3 ubiquitin ligase. Nat.
Biotechnol. 28, 738–742 (2010).
47. Itakura, E., Kishi-Itakura, C. & Mizushima, N. The hairpin-type tail-anchored
SNARE syntaxin 17 targets to autophagosomes for fusion with endosomes/
lysosomes. Cell 151, 1256–1269 (2012).
48. Cottam, E. M., Whelband, M. C. & Wileman, T. Coronavirus NSP6 restricts
autophagosome expansion. Autophagy 10, 1426–1441 (2014).
49. Oudshoorn, D. et al. Expression and cleavage of middle east respiratory
syndrome coronavirusnsp3–4 polyprotein induce the formation of double-
membrane vesicles that mimic those associated with coronaviral RNA
replication. MBio 8, e01658–17 (2017).
50. Muth, D. et al. Attenuation of replication by a 29 nucleotide deletion in SARS-
coronavirus acquired during the early stages of human-to-human
transmission. Sci. Rep. 8, 15177 (2018).
51. Niemeyer, D. et al. Middle East respiratory syndrome coronavirus accessory
protein 4a is a type I interferon antagonist. J. Virol. 87, 12489–12495 (2013).
52. Orvedahl, A. et al. Autophagy protects against Sindbis virus infection of the
central nervous system. Cell Host. Microbe 7, 115–127 (2010).
53. Shoji-Kawata, S. et al. Identiﬁcation of a candidate therapeutic autophagy-
inducing peptide. Nature 494, 201–206 (2013).
54. Malik, S. A. et al. BH3 mimetics activate multiple pro-autophagic pathways.
Oncogene 30, 3918–3929 (2011).
55. Matsunaga, K. et al. Two Beclin 1-binding proteins, Atg14L and Rubicon,
reciprocally regulate autophagy at different stages. Nat. Cell Biol. 11, 385–396
(2009).
56. Wu, C. Y. et al. Small molecules targeting severe acute respiratory syndrome
human coronavirus. Proc. Natl Acad. Sci. USA 101, 10012–10017 (2004).
57. Xu, D. et al. USP14 regulates autophagy by suppressing K63 ubiquitination of
Beclin 1. Genes Dev. 30, 1718–1730 (2016).
58. Xu, C. et al. Regulation of autophagy by E3 ubiquitin ligase RNF216 through
BECN1 ubiquitination. Autophagy 10, 2239–2250 (2014).
59. Liu, C. C. et al. Cul3-KLHL20 ubiquitin ligase governs the turnover of ULK1
and VPS34 complexes to control autophagy termination. Mol. Cell 61, 84–97
(2016).
60. Platta, H. W., Abrahamsen, H., Thoresen, S. B. & Stenmark, H. Nedd4-
dependent lysine-11-linked polyubiquitination of the tumour suppressor
Beclin 1. Biochem. J. 441, 399–406 (2012).
61. Fimia, G. M. et al. Ambra1 regulates autophagy and development of the
nervous system. Nature 447, 1121–1125 (2007).
62. Jin, J., Arias, E. E., Chen, J., Harper, J. W. & Walter, J. C. A family of diverse
Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase
destruction of the replication factor Cdt1. Mol. Cell 23, 709–721 (2006).
63. Xia, P. et al. WASH inhibits autophagy through suppression of Beclin 1
ubiquitination. EMBO J. 32, 2685–2696 (2013).
64. Ashkenazi, A. et al. Polyglutamine tracts regulate beclin 1-dependent
autophagy. Nature 545, 108–111 (2017).
65. Gusho, E., Baskar, D., & Banerjee, S. New advances in our understanding of the
“unique” RNase L in host pathogen interaction and immune signaling. Cytokine
pii: S1043–4666(16)30456–2. https://doi.org/10.1016/j.cyto.2016.08.009 (2016).
66. Yang, Y. et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and
ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are
potent interferon antagonists. Protein Cell 4, 951–961 (2013).
67. Ambjorn, M. et al. IFNB1/interferon-beta-induced autophagy in MCF-7
breast cancer cells counteracts its proapoptotic function. Autophagy 9,
287–302 (2013).
68. Scobey, T. et al. Reverse genetics with a full-length infectious cDNA of the
Middle East respiratory syndrome coronavirus. Proc. Natl Acad. Sci. USA 110,
16157–16162 (2013).
69. Almazán, F. et al. Engineering a replication-competent, propagation-defective
Middle East respiratory syndrome coronavirus as a vaccine candidate. MBio 4,
e00650–13 (2013).
70. Skotland, T., Iversen, T. G., Torgersen, M. L. & Sandvig, K. Cell-penetrating
peptides: possibilities and challenges for drug delivery in vitro and in vivo.
Molecules 20, 13313–13323 (2015).
71. Campbell, G. R. & Spector, S. A. Vitamin D inhibits human
immunodeﬁciency virus type 1 and Mycobacterium tuberculosis infection in
macrophages through the induction of autophagy. PLoS. Pathog. 8, e1002689
(2012).
72. Orvedahl, A. et al. HSV-1 ICP34.5 confers neurovirulence by targeting the
Beclin 1 autophagy protein. Cell Host. Microbe 1, 23–35 (2007).
73. Akhrymuk, I., Kulemzin, S. V. & Frolova, E. I. Evasion of the innate immune
response: the Old World alphavirus nsP2 protein induces rapid degradation of
Rpb1, a catalytic subunit of RNA polymerase II. J. Virol. 86, 7180–7191
(2012).
74. Kim, D. Y. et al. New world and old world alphaviruses have evolved to exploit
different components of stress granules, FXR and G3BP proteins, for assembly
of viral replication complexes. PLoS. Pathog. 12, e1005810 (2016).
75. Galluzzi, L. et al. Molecular deﬁnitions of autophagy and related processes.
EMBO J. 36, 1811–1836 (2017).
76. Smith, T. C., Kinkel, A. W., Gryczko, C. M. & Goulet, J. R. Absorption of
pyrvinium pamoate. Clin. Pharmacol. Ther. 19, 802–806 (1976).
77. Andrews, P., Thyssen, J. & Lorke, D. The biology and toxicology of
molluscicides, Bayluscide. Pharmacol. Ther. 19, 245–295 (1982).
78. Costabile, G. et al. Toward repositioning niclosamide for antivirulence therapy
of pseudomonas aeruginosa lung infections: development of inhalable
formulations through nanosuspension technology. Mol. Pharm. 12,
2604–2617 (2015).
79. Rubinsztein, D. C., Codogno, P. & Levine, B. Autophagy modulation as a
potential therapeutic target for diverse diseases. Nat. Rev. Drug Discov. 11,
709–730 (2012).
80. Rubinsztein, D. C., Bento, C. F. & Deretic, V. Therapeutic targeting of
autophagy in neurodegenerative and infectious diseases. J. Exp. Med. 212,
979–990 (2015).
81. Zschocke, J. et al. Antidepressant drugs diversely affect autophagy pathways in
astrocytes and neurons–dissociation from cholesterol homeostasis.
Neuropsychopharmacology 36, 1754–1768 (2011).
82. Corman, V. M. et al. Detection of a novel human coronavirus by real-time
reverse-transcription polymerase chain reaction. Eur. Surveill. 17, 20285
(2012).
83. Miracco, C. et al. Protein and mRNA expression of autophagy gene Beclin 1 in
human brain tumours. Int J. Oncol. 30, 429–436 (2007).
84. Byrnes, A. P. & Grifﬁn, D. E. Binding of Sindbis virus to cell surface heparan
sulfate. J. Virol. 72, 7349–7356 (1998).
85. Muth, D. et al. Transgene expression in the genome of Middle East
respiratory syndrome coronavirus based on a novel reverse genetics system
utilizing Red-mediated recombination cloning. J. Gen. Virol. 98, 2461–2469
(2017).
86. Tischer, B. K., Smith, G. A. & Osterrieder, N. En passant mutagenesis: a two
step markerless red recombination system. Methods Mol. Biol. 634, 421–430
(2010).
87. Wochnik, G. M. et al. FK506-binding proteins 51 and 52 differentially regulate
dynein interaction and nuclear translocation of the glucocorticoid receptor in
mammalian cells. J. Biol. Chem. 280, 4609–4616 (2005).
88. Kimura, S., Noda, T. & Yoshimori, T. Dissection of the autophagosome
maturation process by a novel reporter protein, tandem ﬂuorescent-tagged
LC3. Autophagy 3, 452–460 (2007).
89. Mizushima, N., Yoshimori, T. & Levine, B. Methods in mammalian autophagy
research. Cell 140, 313–326 (2010).
Acknowledgements
We are indebted to Mikko Taipale and Susan Lindquist for sharing the results of their
FKBP51 interaction screen before publication. We thank Nicolas Heinemann, Anja
Richter (both Charité), Artem Siemens, Maximilian Tschischka (both University of Bonn
Medical Center) for excellent technical assistance. This work was partially funded by a
NARSAD Young Investigator Award by Brain and Behavior Research Foundation,
honoured by P&S Fund (to NCG, Grant ID 25348). NCG was further supported by a
European Research Council starting grant (# 281338, GxE molmech, awarded to Elisa-
beth Binder) within the FP7 framework. CD was supported by the German Research
Council (DFG) grant DFG SPP1596 (DR 772/10–2) and SFB-TR84 (TRR 84/3, A07), the
Federal Ministry of Education and Research (BMBF) grant RAPID (#01KI1723A) and
the EU Horizon 2020 grants COMPARE (# 643476) and EVAg (#653316). MAM was
supported by the VW Foundation (#93345).” The SKP2 mutant plasmids were a kind gift
from Wenyi Wei.
Author contributions
N.C.G., V.M.C., C.D., M.A.M., T.R. designed and conceived the work. N.C.G., D.N.,
D.M., V.M.C., S.M., A.G., K.H., J.P., K.M., A.Z., A.S.Z., A.H., F.H., R.B.-W., M.B.,
B.M.-M., carried out experiments. N.C.G., D.N., D.M., V.M.C., S.M., A.G., K.H., J.P.,
K.M., A.Z., A.S.Z., A.H., F.H., R.B.-W., M.B., B.M.-M., C.D., M.A.M., T.R. analysed data.
N.C.G., C.D., M.A.M., T.R. wrote the main paper text. N.C.G., prepared all ﬁgures. All
authors reviewed the paper.
Competing interests
The authors declare no competing interests.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13659-4 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:5770 | https://doi.org/10.1038/s41467-019-13659-4 | www.nature.com/naturecommunications 15
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
019-13659-4.
Correspondence and requests for materials should be addressed to N.C.G. or T.R.
Peer review information Nature Communications thanks the anonymous reviewers for
their contribution to the peer review of this work. Peer reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13659-4
16 NATURE COMMUNICATIONS |         (2019) 10:5770 | https://doi.org/10.1038/s41467-019-13659-4 | www.nature.com/naturecommunications
